Impressions on Safety Data from EMERALD Subgroup Analysis

Opinion
Video

Expert perspectives on safety data from the EMERALD subgroup analysis, highlighting endocrine therapy–related adverse effects and supportive care strategies.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
3 experts are featured in this series.
1 expert in this video
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
1 expert in this video
Related Content
INAVO120: Inavolisib Triplet Extends OS in PIK3CA-Mutant Breast Cancer

INAVO120: Inavolisib Triplet Extends OS in PIK3CA-Mutant Breast Cancer

Caroline Seymour
May 22nd 2025
Article

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant advanced breast cancer.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Samuraciclib Shows PFS Benefit in Biomarker-Selected HR+ Breast Cancer

Samuraciclib Shows PFS Benefit in Biomarker-Selected HR+ Breast Cancer

Jordyn Sava
May 15th 2025
Article

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver metastases.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

At 10 Years, Pertuzumab Boosts Survival in Early HER2+ Breast Cancer

At 10 Years, Pertuzumab Boosts Survival in Early HER2+ Breast Cancer

Sabrina Serani
May 13th 2025
Article

Adding pertuzumab to standard of care improved survival by 17% in patients with early-stage HER2-positive breast cancer.

Read More

Vidal Discusses Differences in Duration and AEs With Adjuvant CDK4/6i in Breast Cancer

Vidal Discusses Differences in Duration and AEs With Adjuvant CDK4/6i in Breast Cancer

Targeted Oncology Staff
May 13th 2025
Article

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their different dosing approaches and safety profiles can affect their usage in breast cancer.

Read More